Gene polymorphism analysis of Clopidogrel related gene CYP2C19 in patients after coronary artery bypass grafting in Xinjiang
-
摘要: 目的 分析新疆冠状动脉(冠脉)旁路移植术患者氯吡格雷相关基因CYP2C19的基因多态性分布情况。方法 收集2022年5月—2023年12月在新疆维吾尔自治区人民医院心脏及泛血管医学中心行冠脉旁路移植手术的154例患者的全血标本，检测CYP2C19基因的不同基因型。比较汉族与非汉族人群间CYP2C19基因型和氯吡格雷代谢类型的分布情况。结果 非汉族患者CYP2C19*17基因多态性CT基因型频率显著高于汉族患者，差异有统计学意义(P < 0.001)。快代谢型及超快代谢型仅在非汉族患者中出现，且差异有统计学意义(P=0.001 18)。结论 新疆冠脉旁路移植手术患者氯吡格雷相关基因CYP2C19的基因多态性在汉族与非汉族人群间存在差异；快代谢型及超快代谢类型仅在非汉族中出现，且明显高于汉族患者。Abstract: Objective To analyze the genetic polymorphism distribution of Clopidogrel-related gene CYP2C19 in patients undergoing coronary artery transplantation in Xinjiang.Methods The 154 patients who underwent coronary artery transplantation in Xinjiang Uygur Autonomous Region People's Hospital from May 2022 to December 2023 were collected and detected different genotypes of CYP2C19 gene. We compare the distribution of CYP2C19 genotype and Clopidogrel metabolic type between Han and non-Han populations.Results The frequency of CT genotype of CYP2C19*17 gene polymorphism in non-Han patients was significantly higher than that in Han patients, with statistical significance(P < 0.001). Fast metabolic type and ultra-fast metabolic type were found in non-Han patients only.Conclusion There are different expression in the Clopidogrel-related gene CYP2C19 in non-Han populations with coronary artery transplantation in Xinjiang. Fast metabolism type and ultra-fast metabolism type are only found in non-Han patients.
-
Key words:
- coronary artery bypass surgery /
- CYP2C19 gene /
- clopidogrel /
- gene polymorphism /
- nationality
-
-
图 1 CYP2C19基因频率在不同民族中的分布情况
Figure 1. The distribution of CYP2C19 gene frequency in different ethnic groups
表 1 两组一般临床资料
Table 1. General clinical data
例(%), X±S 项目 汉族组(95例) 非汉族组(59例) P值 男 82(86.3) 52(88.1) 0.837 年龄/岁 59.6±8.8 58.3±8.8 0.096 BMI/(kg/m2) 25.6±3.7 28.3±3.7 < 0.001 高血压 72(75.8) 38(64.4) 0.130 糖尿病 48(50.6) 21(35.6) 0.070 冠脉支架植入 18(18.9) 16(27.1) 0.237 急性心肌梗死 19(20.0) 10(16.9) 0.640 不稳定型心绞痛 76(80.0) 49(83.1) 0.721 入院丙氨酸氨基转移酶/(U/L) 49.9±34.5 52.7±37.3 0.822 出院丙氨酸氨基转移酶/(U/L) 28.1±20.9 34.1±25.5 0.111 入院天冬氨酸氨基转移酶/(U/L) 32.2±18.2 35.1±18.8 0.383 出院天冬氨酸氨基转移酶/(U/L) 25.3±20.8 25.8±13.0 0.853 
下载: 导出CSV
表 2 CYP2C19代谢的民族分布
Table 2. Ethnic distribution of CYP2C19 metabolism
例(%) 代谢类型 汉族组
(95例)非汉族组
(59例)χ2值 P值 正常代谢 30(31.6) 25(42.4) 中间代谢 51(53.7) 22(37.3) 慢代谢 14(14.7) 4(6.8) 18.104 0.001 18 快代谢 0 7(11.8) 超快代谢 0 1(1.7)
下载: 导出CSV
-
[1] Ziegelstein RC, Kronish IM, Thombs BD. Depression screening to improve clinical outcomes in coronary heart disease patients[J]. Am Heart J, 2024, 271: 109-111. doi: 10.1016/j.ahj.2024.02.017
[2] GBD 2019 Viewpoint Collaborators. Five insights from the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1135-1159. doi: 10.1016/S0140-6736(20)31404-5
[3] Samano N, Souza D, Dashwood MR. Saphenous veins in coronary artery bypass grafting need external support[J]. Asian Cardiovasc Thora Ann, 2021, 29(5): 457-467. doi: 10.1177/0218492320980936
[4] Rubboli A, Vecchio S. Antiplatelet therapy after coronary bypass grafting: which regimen and for whom?[J]. Eur Heart J Cardiovasc Pharmacother, 2021, 7(6): 527-528. doi: 10.1093/ehjcvp/pvaa091
[5] Gray L, Kuntz G, Ganapathi A, er al. Diagnosis and Treatment of subacute right coronary artery stent thrombosis after dual-antiplatelet therapy interruption for coronary artery bypass grafting surgery[J]. J Cardiothorac Vasc Anesth, 2023, 37(7): 1236-1240. doi: 10.1053/j.jvca.2023.02.038
[6] Zhao H, Wei L, Li H, et al. Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study[J]. Lancet Infect Dis, 2021, 21(6): 847-857. doi: 10.1016/S1473-3099(20)30596-X
[7] Daoulah A, Qenawi W, Alshehri A, et al. Single versus dual antiplatelet therapy after coronary artery bypass grafting for unprotected left-main coronary disease[J]. Crit Pathw Cardiol, 2024, 23(1): 12-16.
[8] Wang W, Shao C, Xu B, et al. CYP2C19 genotype has prognostic value in specific populations following coronary stenting[J]. Ann Transl Med, 2021, 9(13): 1066. doi: 10.21037/atm-20-7724
[9] Wang T, Zhao T, Bao S, et al. CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in North western Xinjiang, China, From2014 Through 2019[J]. Medicine(Baltimore), 2020, 99(29): e20582.
[10] Jin T, Zhang M, Yang H, et al. Genetic polymorphisms of the drug-metabolizing enzyme CYP2C19 in the Uyghur population in northwest China[J]. Xenobiotica, 2016, 46(7): 634-640. doi: 10.3109/00498254.2015.1102986
[11] Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics[J]. Lancet, 2019, 394(10197): 521-532. doi: 10.1016/S0140-6736(19)31276-0
[12] Wake DT, Ilbawi N, Dunnenberger HM, et al. Pharmacogenomics: Prescribing Precisely[J]. Med Clin North Am, 2019, 103(6): 977-990. doi: 10.1016/j.mcna.2019.07.002
[13] Cecchin E, Stocco G. Pharmacogenomics and Personalized Medicine[J]. Genes(Basel), 2020, 11(6): 679-680.
-
图(1)
表(2)
计量
- 文章访问数: 778
- PDF下载数: 129
- 施引文献: 0